Long-term Management of Alcoholic Liver Disease

Clinics in Liver Disease

Volumn 16, Issue 4, 2012, Pages 763-781

  Woo, Garmen A ^a   O'Brien, Christopher ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholic liver disease; AUDIT C; CAGE; Long term management; Nutrition

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; ALCOHOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ANABOLIC ANDROGENIC STEROID; ANTIOXIDANT; BACLOFEN; COLCHICINE; CYTOCHROME P450; DISULFIRAM; ENDOTOXIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; NALTREXONE; ONDANSETRON; PENTOXIFYLLINE; PLACEBO; PROBIOTIC AGENT; PROPYLTHIOURACIL; REACTIVE OXYGEN METABOLITE; S ADENOSYLMETHIONINE; SILYBUM MARIANUM EXTRACT; SILYMARIN; STEROID; TOPIRAMATE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ALCOHOL USE DISORDER IDENTIFICATION TEST; ALCOHOLISM; ANOREXIA; ANTIBODY PRODUCTION; APOPTOSIS; ASCITES; AWARENESS; BACTERIAL PERITONITIS; BODY FAT; BONE DISEASE; CAGE QUESTIONNAIRE; CALORIC INTAKE; CHOLESTASIS; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; CONCENTRATION DIFFICULTY; CONSTIPATION; CYTOKINE PRODUCTION; DIETARY INTAKE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG TOLERABILITY; ENTERIC FEEDING; ENVIRONMENTAL FACTOR; ESOPHAGOGASTRODUODENOSCOPY; FIBROGENESIS; FRACTURE; GENE DELETION; GENETIC PREDISPOSITION; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATIC OSTEODYSTROPHY; HEPATITIS; HEPATITIS C; HEPATORENAL SYNDROME; HETEROZYGOTE; HISPANIC; HUMAN; IMMUNOREGULATION; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM CARE; MALABSORPTION; MALNUTRITION; MENTAL DISEASE; MESOLIMBIC DOPAMINERGIC SYSTEM; MORTALITY; MUSCLE ATROPHY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONALCOHOLIC FATTY LIVER; NUTRITIONAL DISORDER; NUTRITIONAL SUPPORT; OBESITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; OXIDATIVE STRESS; PARENTERAL NUTRITION; PARESTHESIA; PATIENT COUNSELING; PRACTICE GUIDELINE; PREVENTION; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; SCREENING; SEDATION; SEX DIFFERENCE; SIDE EFFECT; STOMACH VARICES BLEEDING; SURGICAL RISK; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TASTE DISORDER; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

FEMALE; HUMANS; LIVER DISEASES, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; MASS SCREENING; NUTRITION THERAPY; PSYCHOTHERAPY; QUESTIONNAIRES; TEMPERANCE; UNITED STATES;

EID: 84867928620     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.08.007     Document Type: Review

References (126)

1. Seth D., Haber P.S., Syn W.K., et al. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol 2011, 26(7):1089-1105.
2. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011, 141(5):1572-1585.
3. Altamirano J., Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011, 8(9):491-501.
4. Day C.P. Who gets alcoholic liver disease: nature or nurture?. J R Coll Physicians Lond 2000, 34(6):557-562.
5. Espinoza P., Ducot B., Pelletier G., et al. Interobserver agreement in the physical diagnosis of alcoholic liver disease. Dig Dis Sci 1987, 32(3):244-247.
6. Day C.P. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006, 26(9):1021-1028.
7. Wilfred de Alwis N.M., Day C.P. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007, 27(1):44-54.
8. Mueller S., Millonig G., Seitz H.K. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol 2009, 15(28):3462-3471.
9. Becker U., Deis A., Sorensen T.I., et al. Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996, 23(5):1025-1029.
10. Fuch C.S., Stampfer M.J., Colditz G.A., et al. Alcohol consumption and mortality among women. N Engl J Med 1995, 332(19):1245-1250.
11. Mas V.R., Fassnacht R., Archer K.J., et al. Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mol Med 2010, 16(7-8):287-297.
12. Siu L., Foont J., Wands J.R. Hepatitis C virus and alcohol. Semin Liver Dis 2009, 29(2):188-199.
13. Frazier T.H., Stocker A.M., Kershner N.A., et al. Treatment of alcoholic liver disease. Ther Adv Gastroenterol 2011, 4(1):63-81.
14. Basra S., Anand B.S. Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol 2011, 3(5):108-113.
15. Marcos M., Pastor I., González-Sarmiento R., et al. A new genetic variant involved in genetic susceptibility to alcoholic liver cirrhosis: -330T>G polymorphism of the interleukin-2 gene. Eur J Gastroenterol Hepatol 2008, 20(9):855-859.
16. Marcos M., Pastor I., González-Sarmiento R., et al. A functional polymorphism of the NFKB1 gene increases the risk for alcoholic liver cirrhosis in patients with alcohol dependence. Alcohol Clin Exp Res 2009, 33(11):1857-1862.
17. To S.E., Vega C.P. Alcoholism and pathways to recovery: new survey results on views and treatment options. MedGenMed 2006, 8(1):2.
18. D'Amico E.J., Paddock S.M., Burnam A., et al. Identification of and guidance for problem drinking by general medical providers: results from a national survey. Med Care 2005, 43(3):229-236.
19. Grucza R.A., Przybeck T.R., Cloninger C.R. Screening for alcohol problems: an epidemiological perspective and implications for primary care. Mo Med 2008, 105(1):67-71.
20. U.S. Preventive Services Task Force Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 2004, 140(7):554-556.
21. Bush B., Shaw S., Cleary P., et al. Screening for alcohol abuse using the CAGE questionnaire. Am J Med 1987, 82(2):231-235.
22. Ewing J.A. Detecting alcoholism. The CAGE questionnaire. JAMA 1984, 252(14):1905-1907.
23. Bradley K.A., Bush K.R., McDonell M.B., et al. Screening for problem drinking: comparison of CAGE and AUDIT. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. J Gen Intern Med 1998, 13(6):379-388.
24. Bradley K.A., Boyd-Wickizer J., Powell S.H., et al. Alcohol screening questionnaires in women: a critical review. JAMA 1998, 280(2):166-171.
25. Saunders J.B., Aasland O.G., Babor T.F., et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993, 88(6):791-804.
26. Steinbauer J.R., Cantor S.B., Holzer C.E., et al. Ethnic and sex bias in primary care screening tests for alcohol use disorders. Ann Intern Med 1998, 129(5):353-362.
27. Kriston L., Holzel L., Weiser A.K., et al. Meta-analysis: are 3 questions enough to detect unhealthy alcohol use?. Ann Intern Med 2008, 149(12):879-888.
28. Frank D., DeBenedetti A.F., Volk R.J., et al. Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race/ethnic groups. J Gen Intern Med 2008, 23(6):781-787.
29. Altamirano J., Bataller R., Cardenas A., et al. Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. Ann Hepatol 2012, 11(2):213-221.
30. Babineaux M.J., Anand B.S. General aspects of the treatment of alcoholic hepatitis. World J Hepatol 2011, 3(5):125-129.
31. Tan H.H., Virmani S., Martin P. Controversies in the management of alcoholic liver disease. Mt Sinai J Med 2009, 76(5):484-498.
32. Lucey M.R. Management of alcoholic liver disease. Clin Liver Dis 2009, 13(2):267-275.
33. Johnson B.A. Medication treatment of different types of alcoholism. Am J Psychiatry 2010, 167(6):630-639.
34. Miller W.R., Walters S.T., Bennett M.E. How effective is alcoholism treatment in the United States?. J Stud Alcohol 2001, 62(2):211-220.
35. Kaner E.F., Dickinson H.O., Beyer F., et al. The effectiveness of brief alcohol interventions in primary care settings: a systemic review. Drug Alcohol Rev 2009, 28(3):301-323.
36. Swift R.M. Drug therapy for alcohol dependence. N Engl J Med 1999, 340(19):1482-1490.
37. Finney J.W., Hahn A.C., Moos R.H. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996, 91(12):1773-1796.
38. Shen M.L., Lipsky J.J., Naylor S. Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase. Biochem Pharmacol 2000, 60(7):947-953.
39. Kershenobich D., Corona D.L., Kershenovich R., et al. Management of alcoholic liver disease: an update. Alcohol Clin Exp Res 2011, 35(5):804-805.
40. Johnson B.A. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008, 75(1):34-56.
41. Snyder J.L., Bowers T.G. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse 2008, 34(4):449-461.
42. Hammarberg A., Nylander I., Zhou Q., et al. The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. Brain Res 2009, 1305(Suppl):S2-S6.
43. Bouza C., Angeles M., Munoz A., et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systemic review. Addiction 2004, 99(7):811-828.
44. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of Baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis; randomized, double-blind controlled study. Lancet 2007, 370(9603):1915-1922.
45. Kenna G.A., Lomastro T.L., Schiesl A., et al. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2009, 2(2):135-142.
46. Johnson B.A., Ait-Daoud N., Bowden C.L., et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003, 361(9370):1677-1685.
47. Johnson B.A., Rosenthal N., Capece J.A., et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298(14):1641-1651.
48. Shank R.P., Gardocki J.F., Streeter A.J., et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41(Suppl 1):S3-S9.
49. Johnson B.A., Ait-Daoud N., Seneviratne C., et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011, 168(3):265-275.
50. Edward S., Kenna G.A., Swift R.M., et al. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des 2011, 17(14):1323-1332.
51. Gramenzi A., Caputo F., Biselli M., et al. Review article: alcoholic liver disease-pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006, 24(8):1151-1161.
52. DiCecco S.R., Francisco-Ziller N. Nutrition in alcoholic liver disease. Nutr Clin Pract 2006, 21(3):245-254.
53. Griffith C.M., Schenker S. The role of nutritional therapy in alcoholic liver disease. Alcohol Res Health 2006, 29(4):296-306.
54. Muller M.J., Lautz H.U., Plogmann B., et al. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. Hepatology 1992, 15(5):782-794.
55. Mendenhall C., Roselle G.A., Gartside P., et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration cooperative studies. Alcohol Clin Exp Res 1995, 19(3):635-641.
56. Halsted C.H. Nutrition and alcoholic liver disease. Semin Liver Dis 2004, 24(3):289-304.
57. McClain C.J., Barve S.S., Barve A., et al. Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res 2011, 35(5):815-820.
58. Hirsch S., de la Maza M.P., Gattas V., et al. Nutritional support in alcoholic cirrhotic patients improves host defenses. J Am Coll Nutr 1999, 18(5):434-441.
59. Swart G.R., Zillikens M.C., van Vuure J.K., et al. Effect of late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ 1989, 200(6709):1202-1203.
60. Verboeket-van de Venne W.P., Westerp K.R., van Hoek B., et al. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food intake. Gut 1995, 36(1):110-116.
61. O'Shea R.S., Dasarathy S., McCullough A.J., et al. AASLD practice guidelines: alcoholic liver disease. Hepatology 2010, 51(1):307-328.
62. Phillips M., Curtis H., Portmann B., et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomized clinical trial. J Hepatol 2006, 44(4):784-790.
63. Stewart S., Prince M., Bassendine M., et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007, 47(2):277-283.
64. Day C.P. Treatment of alcoholic liver disease. Liver Transpl 2007, 13(11 Suppl 2):S69-S75.
65. Assimakoupoulos S.F., Thomopoulos K.C., Labropoulou-Karatza C. Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?. World J Gastroenterol 2009, 15(25):3194-3195.
66. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119(6):1637-1648.
67. McCullough A.J., O'Shea R.S., Dasarathy S. Diagnosis and management of alcoholic liver disease. J Dig Dis 2011, 12(4):257-262.
68. Bergheim I., McClain C.J., Arteel G.E. Treatment of alcoholic liver disease. Dig Dis 2005, 23(3-4):275-284.
69. Orrego H., Blake J.E., Blendis L.M., et al. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987, 317(23):1421-1427.
70. Rambaldi A., Iaquinto G., Gluud C. Anabolic androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002, 97(7):1674-1681.
71. Rambaldi A., Gluud C. Colchicine for alcoholic and nonalcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005, (2). CD002148.
72. Morgan T.R., Weiss D.G., Nemchausky B., et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005, 128(4):882-890.
73. Kershenobich D., Vargas F., Garcia-Tsao G., et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988, 318(26):1709-1713.
74. Morgan T.R., Nemchausky N., Schiff E.R., et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: results of a prospective, randomized, placebo-controlled, multicenter VA trial. Gastroenterology 2002, 122:641. [abstract].
75. Cortez-Pinto H., Alexandrino P., Camilo M.E., et al. Lack of effect of colchicines in alcoholic cirrhosis: final results of a double blind randomized trial. Eur J Gastroenterol Hepatol 2002, 14(4):377-381.
76. Lee T.D., Sadda M.R., Mendler M.H., et al. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004, 28(1):173-181.
77. Mato J.M., Camara J., Fernandez de Paz J., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999, 30(6):1081-1089.
78. Rambaldi A., Gluud C. S-Adenosyl-l-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006, (2). CD002235.
79. McClain C.J., Hill D.B., Song Z., et al. S-adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol 2002, 27(3):185-192.
80. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988, 263(33):17205-17208.
81. Pena L.R., Hill D.B., McClain C.J. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr 1999, 23(1):1-6.
82. Rambaldi A., Jacobs B.P., Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007, (4). CD003620.
83. Rambaldi A., Jacobs B.P., Iaquinto G., et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases-a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005, 100(11):2583-2591.
84. Kirpich I.A., Solovieva N.V., Leikhter S.N., et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008, 42(8):675-682.
85. Lata J., Jurankova J., Kopacova M., et al. Probiotics in hepatology. World J Gastroenterol 2011, 17(24):2890-2896.
86. Forsyth C.B., Farhadi A., Jakate S.M., et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009, 43(2):163-172.
87. Gluud C. Testosterone and alcoholic cirrhosis. Epidemiologic, pathophysiologic, and therapeutic studies in men. Dan Med Bull 1988, 35(6):564-575.
88. Woerdeman J., de Ronde W. Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting. Expert Opin Investig Drugs 2011, 20(1):87-97.
89. Rambaldi A., Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 2006, (4). CD003045.
90. Friedman L.S. Surgery in the patient with liver disease. Trans Am Clin Climatol Assoc 2010, 121:192-204.
91. Garrison R.N., Cryer H.M., Howard D.A., et al. Clarification of risk factors for abdominal operations in patients with hepatitis cirrhosis. Ann Surg 1984, 199(6):648-655.
92. Mansour A., Watson W., Shayani V., et al. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997, 122(4):730-735.
93. Teh S.H., Nagorney D.M., Stevens S.R., et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 2007, 132(4):1261-1269.
94. Lucena M.I., Andrade R.J., Tognoni G., et al. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol 2002, 58(6):435-440.
95. Powell W.J., Klatskin G. Duration and survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968, 44(3):406-420.
96. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000, 33(5):846-852.
97. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. AASLD practice guidelines: prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46(3):922-938.
98. Sanyal A.J., Freedman A.M., Luketic V.A., et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996, 111(1):138-146.
99. McCormick P.A., Dick R., Panagou E.B., et al. Emergency transjugular intrahepatic portosystemic stent shunting as a salvage treatment for uncontrolled variceal hemorrhage. Br J Surg 1994, 81(9):1324-1327.
100. Gines P., Quintero E., Arroyo V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987, 7(1):122-128.
101. Runyon B.A. Ascites and spontaneous bacterial peritonitis. Sleisenger and Fordtran's gastrointestinal and liver disease 2002, 1517-1542. Saunders, Philadelphia. 7th edition. M. Feldman, L.S. Friedman, M.H. Sleisenger (Eds.).
102. Runyon B.A. AASLD practice guideline: management of adult patients with ascites due to cirrhosis. Hepatology 2004, 39(3):841-856.
103. Starr S.P., Raines D. Cirrhosis: diagnosis, management, and prevention. Am Fam Physician 2011, 84(12):1353-1359.
104. Schafer D.F., Jones E.A. Hepatic encephalopathy. Hepatology. A textbook of liver disease 1990, 447-460. W. B. Saunders, Philadelphia. D. Zakim, T.D. Boyer (Eds.).
105. de Melo R.T., Charneski L., Hilas O. Rifaximin for the treatment of hepatic encephalopathy. Am J Health Syst Pharm 2008, 65(9):818-822.
106. Fitz G. Hepatic encephalopathy, hepatopulmonary syndrome, coagulopathy and other complications of chronic liver disease. Sleisenger and Fordtran's gastrointestinal and liver disease 2002, Saunders, Philadelphia. 7th edition. M. Feldman, L.S. Friedman, M.H. Sleisenger (Eds.).
107. Schiano T.D. Complications of chronic liver disease. Current diagnosis and treatment in gastroenterology 2002, 639-663. Lange Current Series. USA: McGraw-Hill Companies. 2nd edition. S. Friedman, J. Grendell, K. McQuaid (Eds.).
108. Blei A.T., Córdoba J. Hepatic encephalopathy. Am J Gastroenterol 2001, 96(7):1968-1976.
109. Abou-Assi S., Vlahcevic Z.R. Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible. Postgrad Med 2001, 109(2):52-54.
110. Arroyo V., Ginès P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996, 23(1):164-176.
111. Magan A.A., Khalil A.A., Ahmed M.H. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol 2010, 16(41):5139-5147.
112. Garcia-Tsao G., Lim J.K., Members of Veterans Affairs Hepatitis C Resource Center Program Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs hepatitis C Resource Center program and the national hepatitis C program. Am J Gastroenterol 2009, 104(7):1802-1829.
113. Ginès P., Guevara M., Arroyo V., et al. Hepatorenal syndrome. Lancet 2003, 362(9398):1819-1827.
114. Bruix J., Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
115. Hassan M.M., Hwang L.Y., Hatten C.J., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002, 36(5):1206-1213.
116. Schoniger-Hekele M., Muller C., Kutilek M., et al. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol 2000, 12(8):941-948.
117. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130(7):417-422.
118. Trevisani F., De N.S., Rapaccini G., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002, 97(3):734-744.
119. López-Larramona G., Lucendo A.J., González-Castillo S., et al. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. World J Hepatol 2011, 3(12):300-307.
120. Gonzalez-Reimers E., Alvisa-Negrin J., Santolaria-Fernandez F., et al. Vitamin D and nutritional status are related to bone fractures in alcoholics. Alcohol Alcohol 2011, 46(2):148-155.
121. Bhagat V., Mindikoglu A.L., Nudo C.G., et al. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009, 15(12):1814-1820.
122. Berlakovich G.A. Wasting your organ with your lifestyle and receiving a new one?. Ann Transplant 2005, 10(1):38-43.
123. Lucey M.R. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011, 17(7):751-759.
124. Vaillant G.E. A 60-year follow-up of alcoholic men. Addiction 2003, 98(8):1043-1051.
125. Burra P., Senzolo M., Adam R., et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010, 10(1):138-148.
126. Watt K.D., Pedersen R.A., Kremers W.K., et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010, 10(6):1420-1427.